Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01751568|
Recruitment Status : Recruiting
First Posted : December 18, 2012
Last Update Posted : June 28, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections Tuberculosis||Drug: Raltegravir||Phase 1 Phase 2|
People who are infected with HIV are also at risk for becoming infected with TB, particularly in many resource-limited settings, including Sub-Saharan Africa. Rifampicin is a medication commonly used to treat TB. There is a need for HIV treatment regimens that contain newer ARV medications that are well-tolerated and have minimal interactions with rifampicin-containing TB medication regimens. This study will enroll HIV-infected infants and children who have never taken any ARV medications or who have not received ARVs for at least 30 days prior to study entry and who are infected with TB and are taking or will be starting a TB medication regimen that includes rifampicin. The purpose of this study is to evaluate the safety and tolerance of raltegravir-containing ARV regimens to treat HIV when administered with a rifampicin-containing regimen to treat TB in infants and children. Study researchers will also evaluate the pharmacokinetics of the medications (i.e., how medication is absorbed and processed in the body) and determine the most effective dose of raltegravir when it is administered with a TB regimen that contains rifampicin.
During the study, researchers will continuously monitor participant data for safety and other factors. Researchers may adjust the dose of raltegravir given to participants prior to enrolling additional participants.
At study entry, participants will undergo a medical and medication history review, physical examination, medication adherence assessment, blood collection, and urine collection. Participants will receive chewable raltegravir tablets twice daily, and they will also take their TB medications, including rifampicin, and two nucleoside reverse transcriptase inhibitor (NRTI) ARV medications that will be chosen by participants' doctors. This study will provide raltegravir to participants; all other medications will be prescribed by participants' own doctors.
At a study visit at Days 5 to 8, participants will remain in the clinic for about 12 hours. They will take part in the same study procedures that occurred at the entry visit, but they will also have small amounts of blood collected several times throughout the 12 hours to measure the amount of medication in the blood. After the Day 5 to 8 visit, participants will begin receiving a fourth ARV medication chosen by their doctor, in addition to the other medications. Participants will continue receiving raltegravir until they stop taking their TB medications. They will continue to take the third ARV medication and the other two ARV medications for 3 months after they stop receiving raltegravir and the TB medications.
Additional study visits will occur at Day 14, Weeks 4 and 8, every 4 weeks until the participant stops receiving raltegravir and the TB medications, and 4 and 12 weeks after stopping raltegravir and the TB medications. These study visits will include the same study procedures that occurred at study entry. Participants will be enrolled in the study for a total of about 4 to 9 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||108 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children|
|Actual Study Start Date :||May 2014|
|Estimated Primary Completion Date :||September 30, 2019|
|Estimated Study Completion Date :||September 30, 2019|
Experimental: 4 Weeks to Less than 12 Years of Age
Participants will receive chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily, in addition to two NRTIs to treat HIV and a rifampicin-containing regimen to treat TB. Participants will be enrolled into the study into three cohorts: Cohort I: 2 years of age to less than 6 years of age, Cohort II: 6 years of age to less than 12 years of age, and Cohort III: 4 weeks of age to less than 2 years of age. After a study visit at Day 5 to 8, a fourth ARV medication will be added to the regimen.
Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily.
- Termination from treatment due to adverse events of greater than or equal to Grade 3 deemed at least possibly related to raltegravir [ Time Frame: Measured through a participant's last study visit, at approximately Month 4 to 9 ]
- Death, Grade 4 life-threatening adverse events deemed at least possibly related to raltegravir [ Time Frame: Measured through a participant's last study visit, at approximately Month 4 to 9 ]
- Grade 4 non-life threatening adverse events deemed as probably or definitely related to raltegravir [ Time Frame: Measured through a participant's last study visit, at approximately Month 4 to 9 ]
- Adverse events of greater than or equal to Grade 3 deemed at least possibly related to raltegravir [ Time Frame: Measured through a participant's last study visit, at approximately Month 4 to 9 ]
- Early termination of TB therapy if there is multi-drug-resistant (MDR)/extensively drug-resistant (XDR) TB detected subsequent to starting ARV treatment or if due to toxicity attributable to TB medication [ Time Frame: Measured through a participant's last study visit, at approximately Month 4 to 9 ]
- Failure to respond at Week 8, which includes HIV RNA (copies/mL) greater than 400 copies/mL AND less than 1-log10 drop from baseline [ Time Frame: Measured at Week 8 ]
- Development of new opportunistic infections (OIs) [ Time Frame: Measured through a participant's last study visit, at approximately Month 4 to 9 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01751568
|Soweto IMPAACT CRS||Recruiting|
|Johannesburg, Gauteng, South Africa, 1862|
|Contact: Nasreen Abrahams, M.B.A., B.Tech 27-11-9899700 firstname.lastname@example.org|
|Wits RHI Shandukani Research Centre CRS||Recruiting|
|Johannesburg, Gauteng, South Africa, 2001|
|Contact: Hermien Gous, Pharm.D. 27-11-3585500 ext 5502 email@example.com|
|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS||Recruiting|
|Cape Town, Western Cape Province, South Africa, 7505|
|Contact: Frieda A. Verheye-Dua 27-21-9389772 Frieda@sun.ac.za|
|Tygerberg, Western Cape Province, South Africa, 7505|
|Contact: Joan Coetzee 27-21-9384157 firstname.lastname@example.org|
|Study Chair:||Tammy Meyers, MD||Bamboo Grove, Wan Chai, Hong Kong, People's Republic of China|
|Study Chair:||Paul Krogstad, MD||University of California, Los Angeles|